Intelligence · Patents
Patents expiring in 2030
Annual patent cliff calendar for 2030 — US pharmaceutical patents by expiration date.
- Patents
- 905
Quick answer
905 indexed pharmaceutical patents have expiration dates in 2030. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7718387
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
granted -
US 7718160
Radiolabeled compounds and liposomes and their method of making and using same
granted -
US 7717728
Electrical Connector
granted -
US 7718670
Quinuclidine amide derivatives
granted -
US 7718769
Tri-peptide hepatitis C serine protease inhibitors
granted -
US 7718196
Rapamycin-resistant T cells and therapeutic uses thereof
granted -
US 7718610
Retrocyclins: antiviral and antimicrobial peptides
granted -
US 7723512
Oligonucleotides comprising a non-phosphate backbone linkage
granted -
US 7723432
Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
granted -
US 7723500
Immunostimulatory nucleic acid molecules
granted -
US 7723300
Regulators of the non-genomic action of progesterone and methods of use
granted -
US 7723474
Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
granted -
US 7723472
Extracellular matrix binding chimeric proteins and methods of use thereof
granted -
US 7723496
Preventives/remedies for cancer
granted -
US 7722865
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
granted -
US 7723375
Metabolites of wortmannin analogs and methods of using the same
granted -
US 7723344
Dipeptidyl peptidase inhibitors
granted -
US 7723322
Fluoride carrier for positron emission tomography
granted -
US 7723317
RNAi modulation of ApoB and uses thereof
granted -
US 7723311
Delivery of bioactive substances to target cells
granted -
US 7723313
Methods and compositions for inhibiting angiogenesis
granted -
US 7723303
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
granted -
US 7723104
Cancer specific promoters
granted -
US 7723071
DNA molecules encoding opioid receptors and methods of use thereof
granted -
US 7723022
Immunostimulatory nucleic acid molecules
granted -
US 7723018
Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade
granted -
US 7722898
Modified-release preparations containing oxcarbazepine and derivatives thereof
granted -
US 7722902
Solid dosage form for providing a dietary supplement
granted -
US 7722862
Regulatory T cells suppress autoimmunity
granted -
US 7723328
Methods of facilitating cell survival using neurotrophin mimetics
granted -
US 7723111
Activated dual specificity lymphocytes and their methods of use
granted -
US 7723096
Agonist peptides of carcinoembryonic antigen (CEA) and nucleic acid sequences encoding the agonist peptides
granted -
US 7722889
Plasmodium liver stage antigens
granted -
US 7723340
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
granted -
US 7723345
Multicyclic amino acid derivatives and methods of their use
granted -
US 7723470
Glycopeptide derivatives and pharmaceutical compositions containing the same
granted -
US 7727534
Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
granted -
US 7727544
Treatment of myopia
granted -
US 7728148
Acyclic oximyl hepatitis C protease inhibitors
granted -
US 7727999
Spiroazacyclic compounds as monoamine receptor modulators
granted -
US 7728127
Cross-linked glycopeptide-cephalosporin antibiotics
granted -
US 7727554
Sustained-release nanoparticle compositions and methods for using the same
granted -
US 7728104
Process for preparing glycopeptide phosphonate derivatives
granted -
US 7728120
EML4-ALK fusion gene
granted -
US 7728006
Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
granted -
US 7727542
Bioactive materials, methods of making bioactive materials and method of use thereof
granted -
US 7728004
Crystalline form of a quinolinone-carboxamide compound
granted -
US 7727992
Gyrase inhibitors and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2030?
905 published patents in our USPTO index have expiration dates falling in calendar year 2030.